Givosiran - Open Access .click

Results 121 to 130 of about 1,115 (145)

Some of the next articles are maybe not open access.

Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran

Journal of Inherited Metabolic Disease, 2021
AbstractAcute intermittent porphyria (AIP) is a rare metabolic disease caused by mutations within the hydroxymethylbilane synthase gene. Previous studies have reported increased levels of plasma total homocysteine (tHcy) in symptomatic AIP patients. In this study, we present long‐term data for tHcy and related parameters for an AIP patient cohort (n ...
Jordi To‐Figueras +9 more
openaire +2 more sources

Givosiran — Running RNA Interference to Fight Porphyria Attacks

New England Journal of Medicine, 2020
The porphyrias are a group of rare and ultra-rare devastating disorders of heme biosynthesis. The majority of these disorders are inherited, and patients present with disabling symptoms that have a...
openaire +2 more sources

Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria

Clinical Pharmacology & Therapeutics, 2020
Givosiran is a small interfering ribonucleic acid agent that was recently approved in the United States for the treatment of acute hepatic porphyria (AHP). This phase I study evaluated the safety, pharmacokinetic, and pharmacodynamic profile of subcutaneously (SC) administered givosiran in patients with acute intermittent porphyria, the most common AHP
Sagar, Agarwal +6 more
openaire +2 more sources

Givosiran

Reactions Weekly, 2021
openaire +1 more source

Givosiran

Reactions Weekly, 2023
openaire +1 more source

Givosiran

Reactions Weekly, 2022
openaire +1 more source

Givosiran/hemin

Reactions Weekly, 2022
openaire +1 more source

Cetirizine/givosiran

Reactions Weekly, 2021
openaire +1 more source

Givosiran als neue therapeutische Option